Athens, Ga.
Boehringer Ingelheim began construction in December of 2017 on a 50,000-sf expansion of its 350,000-sf animal vaccine production facility in Athens, Ga. The completed 400,000-sf project will begin commercial operations in mid-2019. Boehringer Ingelheim will also construct a 13,000-sf addition for the manufacture of livestock animal vaccines on its 700,000-sf campus in St. Joseph, Mo.
